ALS-linked TDP43 protein found to control DNA repair, connecting ALS to cancer and dementia

TDP43 is a protein that researchers have spent years studying in the context of ALS and frontotemporal dementia. It misbehaves in both diseases, clumping in places it should not and disappearing from the cell nucleus where it is supposed to work. A new discovery adds a layer to that picture that nobody fully anticipated: TDP43 also controls a specific DNA repair process, and when it fails at that job, the consequences may extend beyond neurodegeneration into cancer biology as well.

What TDP43 was already known to do

TDP43 is an RNA-binding protein. Its primary known functions involve regulating gene expression, helping to process messenger RNA, and controlling which genes get spliced and when. In healthy neurons, TDP43 stays mostly in the nucleus, doing that regulatory work. In approximately 97 percent of ALS cases and around 45 percent of frontotemporal dementia cases, TDP43 mislocalizes out of the nucleus and forms toxic aggregates in the cytoplasm. When that happens, motor neurons and certain brain cells begin to die.

What researchers did not fully appreciate until now was that TDP43 also has a role in the nucleus that goes beyond RNA processing. The new findings show it participates directly in DNA damage response pathways, specifically in a repair mechanism called non-homologous end joining, which cells use to fix double-strand breaks in DNA.

The DNA repair connection explained

Double-strand breaks are among the most serious forms of DNA damage a cell can sustain. Both strands of the DNA helix are severed, and if the break is not repaired accurately and quickly, the cell either dies or accumulates mutations. Non-homologous end joining is the cell's faster but less precise repair option, used especially in neurons, which do not divide and therefore cannot use the more accurate homologous recombination pathway.

The research team found that TDP43 is recruited to sites of DNA double-strand breaks in the nucleus. It interacts with components of the non-homologous end joining machinery to help coordinate the repair. When TDP43 is absent from the nucleus, as happens in ALS and frontotemporal dementia, double-strand breaks accumulate in neurons without being properly resolved. That DNA damage buildup is now a plausible direct contributor to neuronal death in these diseases, separate from the toxic aggregation effects that have already been studied.

Where cancer enters the picture

The cancer connection comes from a different direction. In some tumor types, TDP43 is overexpressed rather than depleted. The research team found that in cancer cells with elevated TDP43, the protein's involvement in DNA repair actually helps those cells survive DNA damage that would otherwise trigger cell death. Chemotherapy and radiation both work partly by inducing DNA damage that overwhelms the cell's repair capacity. If TDP43 overexpression makes cancer cells more efficient at repairing that damage, it could be one mechanism behind treatment resistance.

This is not the first time a protein associated with neurodegeneration has turned up in cancer research. Several other RNA-binding proteins implicated in ALS, including FUS and EWSR1, have known roles in cancer biology. The pattern is beginning to look less like coincidence and more like a shared vulnerability in the cell biology that connects two seemingly unrelated disease categories.

Why this matters for ALS treatment research

ALS has no cure and only two FDA-approved drugs that modestly slow progression in some patients. Riluzole, approved in 1995, extends survival by roughly two to three months on average. Edaravone, approved in 2017, showed benefit in a specific patient subgroup but failed to replicate that result in a broader population trial. The disease has been extraordinarily difficult to treat in part because the biological mechanisms driving motor neuron death have not been fully mapped.

Identifying DNA repair failure as a direct consequence of TDP43 loss from the nucleus adds a concrete, targetable mechanism to that map. It raises the possibility that drugs already developed to modulate DNA repair pathways in cancer, some of which are already in clinical use, could be repurposed or adapted for ALS. The research team noted that this line of investigation is now an active area of follow-up work.

What the findings mean for frontotemporal dementia

Frontotemporal dementia is the second most common form of dementia in people under 65, after early-onset Alzheimer's disease. Like ALS, it has no approved disease-modifying treatment. The two diseases share so much pathology that many neurologists consider them part of a single disease spectrum rather than distinct conditions, and roughly 15 percent of ALS patients develop frontotemporal dementia symptoms during the course of their illness.

If TDP43-related DNA repair failure contributes to neuronal death in ALS motor neurons, the same mechanism almost certainly applies in the frontal and temporal lobe neurons affected in frontotemporal dementia. A treatment strategy that restores TDP43's nuclear function or compensates for its DNA repair role would therefore potentially address both conditions rather than requiring separate approaches for each.

The next steps in TDP43 research

The research team is currently working to identify exactly which molecular interactions TDP43 uses to recruit to DNA break sites and which components of the non-homologous end joining complex it directly contacts. Pinning down those interactions would reveal specific points where a drug could intervene to restore the repair function without needing to address TDP43 aggregation directly, which has proven extremely difficult to target therapeutically.

Separately, the team plans to examine patient-derived neurons carrying ALS-associated TDP43 mutations to measure whether DNA damage accumulation in those cells correlates with disease severity. If the correlation holds, DNA damage load in motor neurons could eventually serve as a biomarker for tracking disease progression in clinical trials, giving researchers a more direct readout than current functional measures like breathing capacity or muscle strength scores.